University of Pittsburgh(x)
The University of Pittsburgh conducts over $620 million in sponsored research annually, and ranks 6th in National Institutes of Health awards. This research activity generates over 200 invention disclosures on an annual basis, which are evaluated by the Office of Technology Management (OTM) in conjunction with the University Technology Transfer Committee for technical merit, market potential and patentability. Over 50 licenses or option agreements are executed yearly and 60 companies have been spun out of the university from 1996 to 2006.
The Office of Technology Management actively seeks to license the University’s IP portfolio to existing companies and also plays a founder role in the formation of new companies around platform technologies. The OTM also assists outside companies in identifying research collaborators within the University and in negotiating sponsored research agreements for such collaborations. It is in this capacity that OTM serves as “the bridge between science and business” at the University of Pittsburgh.
posted by University of Pittsburgh
on 07/25/2008
in Devices, Biomedical
Inventors at the University of Pittsburgh have developed a brain-machine interface that collects and interrupts a subject’s cortical brain signals to control direct, real-time movement of a multi-j...
posted by University of Pittsburgh
on 07/25/2008
in Therapeutic, Biomedical, Drug Discovery
This invention provides for compositions of a stably incorporated fragment of a non-protein coding genomic DNA that prevents cancer stem cell differentiation.
posted by University of Pittsburgh
on 07/25/2008
in Therapeutic, Biomedical, Drug Discovery
University of Pittsburgh researchers who have been studying those secretion dynamics have developed an invention, related to the field of imaging intracellular proteins, which uses fluorescent prob...
posted by University of Pittsburgh
on 07/25/2008
in Diagnostic, Therapeutic, Biomedical
Investigators at the University of Pittsburgh have identified and characterized novel EGFR tumor-associated antigen (TAA) epitopes and enhanced agonist epitopes. Preclinical studies indicate that t...
posted by University of Pittsburgh
on 07/25/2008
in Diagnostic, Biomedical
Inventors at the University of Pittsburgh have developed a panel of biomarkers to diagnose or predict aggressive metastasis to the bone from prostate cancer.
posted by University of Pittsburgh
on 07/18/2008
in Therapeutic, Biomedical, Drug Delivery
The inventors have created a surfactant based version of an inhaled medication marketed for the treatment of pulmonary infections in cystic fibrosis using the antibiotic, tobramycin. It is believe...
posted by University of Pittsburgh
on 07/14/2008
in Therapeutic, Biomedical, Drug Discovery
Investigators at the University of Pittsburgh have found that c-Kit activation on dendritic cells is central to the process of allergic response. The investigators show that genes encoding c-Kit a...
posted by University of Pittsburgh
on 07/14/2008
in Therapeutic, Biomedical
Dr. DeLeo and colleagues have identified and characterized a novel aldehyde dehydrogenase I family member A1(ALDH1A1) tumor associated antigen. Preclinical studies indicate that this agonist epitop...
posted by University of Pittsburgh
on 07/14/2008
in Therapeutic, Biomedical
This method of using ethyl pyruvate has been shown to prevent scarring/fibrotic response in wounds, such as eye wound from refractive surgery and skin wounds.
posted by University of Pittsburgh
on 07/14/2008
in Process/Procedure, Materials
This technology involves a chip-scale implementation of AES for elemental analysis.
